重组活性Ⅶ因子治疗18例危重出血患者临床疗效分析  

Clinical analysis of recombinant activated factor VIIa for 18 patients with severe bleeding

作　　者：刘子玲[1] 杨雷[1] 刘蒙蒙[1] 白欧[1] 崔久嵬[1] 李佩桐[1] 李薇[1] 

机构地区：[1]吉林大学第一医院血液科,长春130021

出　　处：《中华血液学杂志》2012年第5期409-411,共3页Chinese Journal of Hematology

摘　　要：目的寻找一种快速有效的止血方法，降低危重出血患者的死亡率。方法对18例由于各种原因弓l起的危重出血患者应用重组活性Ⅶ因子（rFⅦa）进行治疗并回顾性分析其临床疗效。结果18例危重出血患者中，13例治愈，3例显效，2例无效，临床总有效率达88．89％。其中6例DIC患者，应用rFⅦa12h内PT、APTr、纤维蛋白原恢复正常；13例可评价出血量患者，应用rFⅦa后出血迅速停止，最快起效时间为10rain。结论rFⅦa可以迅速控制出血，对凝血异常、血小板减少、病理产科等多种原因引起的危重出血均有效，在常规处理无效时，应用rFⅦa可以减少患者死亡率。Objective To find a kind of quick and effective haemostasis to decrease the mortality of severe bleeding. Methods 18 severe bleeding patients with different cause received recombinant activated factor Ⅶa（rFⅦa） were analyzed retrospectively. Results Of total 18 cases with severe bleeding, 13 cases cured, 3 cases were effective, 2 cases ineffective. The total clinical effective rate is 88.89%. After using rF Ⅶa, the PT, AF1T and fibrinogen level of 6 DIC patients returned to normal within 12 hours; 13 patients whose the amount of bleeding can be evaluated stopped bleeding quickly. The fastest onset time was 10 rain. Conclusion rFVIIa can stanch severe bleeding for a variety of reasons rapidly and effectively, including coagulopathy, thrombocytopenia, and obstetric hemorrhage. Application of rFⅦa may decrease mortality, when conventional treatment is not valid.

关 键 词：出血 危重病人治疗 重组活性Ⅶ因子 

分 类 号：R459.7[医药卫生—急诊医学]